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Bio-Medical
Detection of Only Viable Bacterial Spores Using a Live/Dead
Indicator in Mixed Populations
This technology can be used by the food and phar maceutical industries to validate sterility and quality.
NASA’s Jet Propulsion Laboratory, Pasadena, California
This method uses a photoaffinity label
that recognizes DNA and can be used to
distinguish populations of bacterial cells
from bacterial spores without the use of
heat shocking during conventional cul-
ture, and live from dead bacterial spores
using molecular-based methods.
Biological validation of commercial
sterility using traditional and alterna-
tive technologies remains challenging.
Recovery of viable spores is cumber-
some, as the process requires substan-
tial incubation time, and the extended
time to results limits the ability to
quickly evaluate the efficacy of existing
technologies. Nucleic acid amplifica-
tion approaches such as PCR (poly-
merase chain reaction) have shown
promise for improving time to detec-
tion for a wide range of applications.
Recent real-time PCR methods are par-
ticularly promising, as these methods
can be made at least semi-quantitative
by correspondence to a standard curve.
Nonetheless, PCR-based methods are
rarely used for process validation,
largely because the DNA from dead
bacterial cells is highly stable and
hence, DNA-based amplification meth-
ods fail to discriminate between live
and inactivated microorganisms.
Currently, no published method has
been shown to effectively distinguish be-
tween live and dead bacterial spores.
This technology uses a DNA binding
photoaffinity label that can be used to
distinguish between live and dead bacte-
rial spores with detection limits ranging
from 109 to 102 spores/mL.
An environmental sample suspected
of containing a mixture of live and dead
vegetative cells and bacterial en-
dospores is treated with a photoaffinity
label. This step will eliminate any vege-
tative cells (live or dead) and dead en-
dospores present in the sample. To fur-
ther determine the bacterial spore
viability, DNA is extracted from the
spores and total population is quanti-
fied by real-time PCR.
The current NASA standard assay
takes 72 hours for results. Part of this
procedure requires a heat shock step at
80 °C for 15 minutes before the sample
can be plated. Using a photoaffinity
label would remove this step from the
current assay as the label readily pene-
trates both live and dead bacterial cells.
Secondly, the photoaffinity label can
only penetrate dead bacterial spores,
leaving behind the viable spore popula-
tion. This would allow for rapid bacterial
spore detection in a matter of hours
compared to the several days that it takes
for the NASA standard assay.
This work was done by Alberto E. Behar of
Caltech; Christina N. Stam of Oak Ridge As-
sociated Universities; and Ronald Smiley of
the U.S. Food and Drug Administration for
NASA’s Jet Propulsion Laboratory. For more
information, contact iaoffice@jpl.nasa.gov.
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The ability to stabilize and treat pa-
tients on exploration missions will de-
pend on access to needed consumables.
Intravenous (IV) fluids have been iden-
tified as required consumables. A review
of the Space Medicine Exploration
Medical Condition List (SMEMCL) lists
over 400 medical conditions that could
present and require treatment during
ISS missions.
The Intravenous Fluid Generation
System (IVGEN) technology provides
the scalable capability to generate IV
fluids from indigenous water supplies.
It meets USP (U.S. Pharmacopeia)
standards. This capability was per-
formed using potable water from the
ISS; water from more extreme environ-
ments would need preconditioning.
The key advantage is the ability to fil-
ter mass and volume, providing the
equivalent amount of IV fluid: this is
critical for remote operations or re-
source-poor environments. The
IVGEN technology purifies drinking
water, mixes it with salt, and transfers
it to a suitable bag to deliver a sterile
normal saline solution.
Operational constraints such as mass
limitations and lack of refrigeration
may limit the type and volume of such
fluids that can be carried onboard the
spacecraft. In addition, most medical
fluids have a shelf life that is shorter
than some mission durations. Conse-
quently, the objective of the IVGEN ex-
periment was to develop, design, and
validate the necessary methodology to
purify spacecraft potable water into a
normal saline solution, thus reducing
the amount of IV fluids that are in-
cluded in the launch manifest.
As currently conceived, an IVGEN sys-
tem for a space exploration mission
would consist of an accumulator, a puri-
fier, a mixing assembly, a salt bag, and a
sterile bag. The accumulator is used to
transfer a measured amount of drinking
water from the spacecraft to the purifier.
The purifier uses filters to separate any
air bubbles that may have gotten
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This system can be used in remote medical facilities where limitations such as lack of
refrigeration may limit the type and volume of medical fluids being stored or transported. 
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trapped during the drinking water trans-
fer from flowing through a high-quality
deionizing cartridge that removes the
impurities in the water before entering
the salt bag and mixing with the salt to
create a normal saline solution.
This work was done by John McQuillen and
Terri McKay of Glenn Research Center, and
Daniel Brown and John Zoldak of ZIN Tech-
nologies. Inc. Further information is con-
tained in a TSP (see page 1).Inquiries con-
cerning rights for the commercial use of this
invention should be addressed to NASA Glenn
Research Center, Innovative Partnerships Of-
fice, Attn: Steven Fedor, Mail Stop 4–8, 21000
Brookpark Road, Cleveland, Ohio 44135.
Refer to LEW-19044-1.
